Stock listing
Shanghai:688222 Hitgen Inc. (成都先导) 股价
Follow Hitgen Inc. into a list and get an email when it puts out news.
Share price · SSE:688222
¥25.87 CNY -3.18 (-10.9%)
Close on Nov 20, 2026
- Day range
- ¥25.42 – ¥27.12 CNYNov 20, 2026
- Volume
- 21.45M sharesNov 20, 2026
- Market cap
- ¥10.38B CNYAt the close on Nov 20, 2026 · price × 401.2M shares outstanding
- 52-week range
- ¥21.46 – ¥47.58 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥861.8M CNYMedian day 22.58M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688222 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥25.87 | -3.18 | -10.9% | ¥26.00 | ¥27.12 | ¥25.42 | 21,447,019 | |
| ¥29.05 | -5.85 | -16.8% | ¥35.00 | ¥35.29 | ¥28.88 | 34,221,928 | |
| ¥34.90 | +0.25 | +0.7% | ¥34.39 | ¥35.91 | ¥33.90 | 16,164,414 | |
| ¥34.65 | -3.34 | -8.8% | ¥37.10 | ¥37.70 | ¥34.33 | 20,888,874 | |
| ¥37.99 | -2.86 | -7.0% | ¥40.17 | ¥40.21 | ¥37.00 | 30,091,929 | |
| ¥40.85 | +2.03 | +5.2% | ¥38.99 | ¥41.66 | ¥38.53 | 35,412,376 | |
| ¥38.82 | +1.52 | +4.1% | ¥36.79 | ¥38.85 | ¥36.37 | 23,547,794 | |
| ¥37.30 | +0.38 | +1.0% | ¥38.00 | ¥38.48 | ¥36.48 | 22,072,721 | |
| ¥36.92 | +1.75 | +5.0% | ¥35.60 | ¥37.89 | ¥35.60 | 25,823,655 | |
| ¥35.17 | -3.15 | -8.2% | ¥36.50 | ¥38.00 | ¥35.09 | 28,910,500 | |
| ¥38.32 | +2.71 | +7.6% | ¥35.00 | ¥39.50 | ¥34.80 | 35,845,137 | |
| ¥35.61 | +2.05 | +6.1% | ¥33.25 | ¥36.10 | ¥31.22 | 32,222,515 | |
| ¥33.56 | -3.95 | -10.5% | ¥36.86 | ¥36.92 | ¥33.50 | 28,942,733 | |
| ¥37.51 | +0.76 | +2.1% | ¥36.30 | ¥37.81 | ¥34.78 | 29,599,976 | |
| ¥36.75 | +0.32 | +0.9% | ¥35.53 | ¥39.90 | ¥33.38 | 35,584,745 | |
| ¥36.43 | -0.02 | -0.1% | ¥36.48 | ¥37.96 | ¥35.75 | 29,663,916 | |
| ¥36.45 | +2.96 | +8.8% | ¥34.03 | ¥36.97 | ¥33.61 | 25,429,629 | |
| ¥33.49 | -1.79 | -5.1% | ¥35.85 | ¥36.18 | ¥33.45 | 17,234,205 | |
| ¥35.28 | -1.80 | -4.9% | ¥36.68 | ¥37.48 | ¥35.15 | 19,793,787 | |
| ¥37.08 | +1.88 | +5.3% | ¥34.50 | ¥37.60 | ¥33.35 | 24,706,587 | |
| ¥35.20 | -1.94 | -5.2% | ¥37.05 | ¥37.99 | ¥35.00 | 23,572,449 | |
| ¥37.14 | -0.54 | -1.4% | ¥38.00 | ¥38.80 | ¥36.76 | 23,514,616 | |
| ¥37.68 | +1.70 | +4.7% | ¥35.73 | ¥38.77 | ¥34.81 | 28,502,354 | |
| ¥35.98 | +0.35 | +1.0% | ¥36.21 | ¥37.68 | ¥33.58 | 24,016,059 | |
| ¥35.63 | -0.52 | -1.4% | ¥37.43 | ¥40.32 | ¥35.24 | 26,063,935 | |
| ¥36.15 | -0.86 | -2.3% | ¥35.81 | ¥38.12 | ¥35.61 | 16,440,410 | |
| ¥37.01 | -1.35 | -3.5% | ¥38.36 | ¥38.93 | ¥37.01 | 12,319,215 | |
| ¥38.36 | -0.62 | -1.6% | ¥38.00 | ¥38.96 | ¥36.57 | 16,069,105 | |
| ¥38.98 | -2.47 | -6.0% | ¥41.89 | ¥42.50 | ¥38.98 | 16,392,864 | |
| ¥41.45 | -0.47 | -1.1% | ¥41.74 | ¥42.44 | ¥39.22 | 21,803,508 | |
| ¥41.92 | -2.77 | -6.2% | ¥43.83 | ¥44.02 | ¥41.72 | 24,404,907 | |
| ¥44.69 | +1.01 | +2.3% | ¥43.50 | ¥46.22 | ¥42.81 | 27,817,271 | |
| ¥43.68 | 0.00 | 0.0% | ¥43.00 | ¥45.18 | ¥42.15 | 19,647,524 | |
| ¥43.68 | -0.51 | -1.2% | ¥44.50 | ¥44.70 | ¥42.61 | 21,846,826 | |
| ¥44.19 | -1.83 | -4.0% | ¥45.55 | ¥46.30 | ¥44.19 | 23,089,787 | |
| ¥46.02 | +1.62 | +3.6% | ¥44.48 | ¥47.58 | ¥43.51 | 34,039,474 | |
| ¥44.40 | -1.08 | -2.4% | ¥45.58 | ¥45.83 | ¥43.80 | 36,652,145 | |
| ¥45.48 | +5.51 | +13.8% | ¥41.65 | ¥46.56 | ¥40.78 | 44,390,938 | |
| ¥39.97 | +2.29 | +6.1% | ¥39.00 | ¥41.64 | ¥38.30 | 37,562,150 | |
| ¥37.68 | +1.06 | +2.9% | ¥36.46 | ¥37.90 | ¥35.83 | 27,040,691 | |
| ¥36.62 | +4.51 | +14.0% | ¥32.18 | ¥37.19 | ¥31.75 | 30,684,613 | |
| ¥32.11 | -0.38 | -1.2% | ¥32.40 | ¥32.80 | ¥31.96 | 9,863,593 | |
| ¥32.49 | +2.00 | +6.6% | ¥30.34 | ¥32.70 | ¥30.21 | 14,400,525 | |
| ¥30.49 | -0.78 | -2.5% | ¥30.69 | ¥31.12 | ¥29.60 | 11,185,874 | |
| ¥31.27 | -1.13 | -3.5% | ¥32.11 | ¥32.13 | ¥30.88 | 12,113,727 | |
| ¥32.40 | -0.05 | -0.2% | ¥31.89 | ¥33.30 | ¥31.72 | 19,468,406 | |
| ¥32.45 | +0.86 | +2.7% | ¥31.66 | ¥32.65 | ¥31.13 | 19,797,185 | |
| ¥31.59 | +0.15 | +0.5% | ¥31.97 | ¥32.29 | ¥31.35 | 10,721,359 | |
| ¥31.44 | -0.97 | -3.0% | ¥32.70 | ¥32.89 | ¥31.13 | 15,351,798 | |
| ¥32.41 | +0.04 | +0.1% | ¥32.40 | ¥33.00 | ¥31.58 | 13,575,685 | |
| ¥32.37 | -0.06 | -0.2% | ¥32.47 | ¥32.98 | ¥31.70 | 16,871,672 | |
| ¥32.43 | +0.19 | +0.6% | ¥32.06 | ¥32.91 | ¥31.50 | 13,979,236 | |
| ¥32.24 | -0.62 | -1.9% | ¥31.01 | ¥32.34 | ¥30.90 | 16,937,422 | |
| ¥32.86 | -0.86 | -2.6% | ¥33.65 | ¥34.55 | ¥32.81 | 16,350,367 | |
| ¥33.72 | -0.09 | -0.3% | ¥34.79 | ¥35.34 | ¥32.93 | 18,893,289 | |
| ¥33.81 | -1.12 | -3.2% | ¥34.88 | ¥35.48 | ¥33.44 | 17,680,281 | |
| ¥34.93 | +0.25 | +0.7% | ¥34.34 | ¥35.53 | ¥33.63 | 19,059,939 | |
| ¥34.68 | -1.48 | -4.1% | ¥36.63 | ¥37.25 | ¥34.24 | 16,207,078 | |
| ¥36.16 | -2.54 | -6.6% | ¥37.16 | ¥38.00 | ¥35.66 | 24,474,052 | |
| ¥38.70 | +3.55 | +10.1% | ¥38.00 | ¥40.57 | ¥36.68 | 32,593,295 |
- Ticker
- Shanghai:688222
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 3, 2026
(688222)"HitGen Inc."Announcement on Introduction of Investor by Investee Company and Passive Formation of Related Party Transaction
Latest news
(688222)"HitGen Inc."Announcement on Introduction of Investor by Investee Company and Passive Formation of Related Party Transaction
Nov 3, 2026
Closed ¥33.56 (-10.5%) on Nov 3, 2026
(688222)"HitGen Inc."Report for Q3 2026
Oct 29, 2026
Closed ¥36.43 (-0.1%) on Oct 29, 2026
(688222)"HitGen Inc."Announcement on Convening the Q3 2026 Performance Briefing
Oct 29, 2026
Closed ¥36.43 (-0.1%) on Oct 29, 2026
(688222)"HitGen Inc."Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration Changes
Oct 29, 2026
Closed ¥36.43 (-0.1%) on Oct 29, 2026
Announcement on Issuance Results of the 1st Tranche of Sci-Tech Innovation Bonds for 2026
Sep 29, 2026
Closed ¥43.68 (0.0%) on Sep 29, 2026
Announcement on Vesting Results for the First Vesting Period under the 2025 Restricted Share Incentive Plan and Listing of Shares
Sep 24, 2026
Closed ¥44.19 (-4.0%) on Sep 24, 2026
Announcement on Receipt of the Notice of Registration Acceptance from the National Association of Financial Market Institutional Investors
Sep 8, 2026
Closed ¥32.45 (+2.7%) on Sep 8, 2026
Announcement on Shareholding Reduction Plan of Shareholder Shenzhen Juntian Investment Enterprise (Limited Partnership)
Aug 29, 2026
Closed ¥32.24 (-1.9%) on Aug 31, 2026
Announcement on Resolutions of the 9th Meeting of the 3rd Board of Directors
Aug 27, 2026
Closed ¥33.72 (-0.3%) on Aug 27, 2026
Announcement on Results of Shareholding Reduction by Shareholder Shenzhen Juntian Investment Enterprise (Limited Partnership)
Aug 14, 2026
Closed ¥38.64 (-3.1%) on Aug 14, 2026
Hitgen Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 67 in all · newest Nov 3, 2026 · oldest 2021
Valuation
EV/sales 13.6× against a median of 52.7×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥9.58B CNY
- P/E
- 66.5×
- EV/sales
- 13.6×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.5×
- Gross margin
- 57.1%
- Operating margin
- 30.0%
- Net margin
- 22.1%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hitgen Inc. Class A · SSE:688222 | US$1.56B | US$1.44B | 66.5× | 13.6× | n/a | 6.5× | 22.1% | 0.2× | n/a |
| Zenas BioPharma, Inc. · NASDAQ:ZBIO | US$1.62B | US$1.26B | n/a | 114× | n/a | 7.6× | n/a | 1.1× | 1.05 |
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Median of the others | US$1.46B | US$1.30B | 52.7× | 31.4× | 2.9× | −229.4% | 0.1× | 1.17 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.10 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.40 · 1 analyst
- Revenue, year to Dec 2026
- 712.3M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jin Li | Chairman&CEO |
| Hongge Liu | Chief Financial Officer |
| Shiwei Geng | Board Secretary |
| Dengfeng Dou | Vice President |
| Guansai Liu | Senior Vice President |
| JJ Chen | Vice President |
| Shimiao Yu | Vice President |
Board
| Director | Role |
|---|---|
| Jin Li | Chairman&CEO |
| Suibo Li 董事 | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · Before open | +8.8% |
| Q1 2023 | Apr 28, 2023 · Before open | +5.4% |
| Q3 2022 | Oct 28, 2022 · Before open | −3.1% |
| Q2 2022 | Aug 26, 2022 · After close | −11.7% |
| Q1 2022 | Apr 28, 2022 · After close | +5.3% |
| Quarter to Sep 30, 2021 | Oct 29, 2021 · Before open | +0.6% |
| Quarter to Jun 30, 2021 | Aug 27, 2021 · After close | +9.3% |
| Quarter to Mar 31, 2021 | Apr 29, 2021 · After close | −2.0% |
| Q4 2020 | Feb 26, 2021 · Before open | +3.5% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 525.6M | 427.0M | 371.3M | 329.7M | 311.1M | 243.6M | 264.2M |
| Cost of revenue | 240.6M | 205.5M | 188.5M | 172.5M | 164.8M | 50.3M | 48.7M |
| Gross profit | 285.0M | 221.4M | 182.9M | 157.2M | 146.3M | 193.3M | 215.4M |
| Research and development | 71.6M | 67.3M | 79.6M | 87.4M | 73.7M | 99.9M | 91.5M |
| Selling, general and administrative | 33.3M | 25.2M | 24.8M | 23.4M | 21.3M | 17.4M | 26.4M |
| Operating income | 132.7M | 86.6M | 34.3M | -5.01M | 35.2M | 62.4M | 124.0M |
| Depreciation and amortization | 48.0M | 45.8M | 45.3M | 44.3M | 45.4M | 19.0M | 13.3M |
| EBITDA | 180.7M | 132.3M | 79.6M | 39.3M | 80.7M | 81.3M | 137.3M |
| Interest expense | 11.3M | 13.0M | 13.0M | 9.83M | 6.56M | 839.2K | 572.6K |
| Income before tax | 120.9M | 62.8M | 35.4M | 12.4M | 55.8M | 63.4M | 132.8M |
| Net income | 109.5M | 51.4M | 40.7M | 25.3M | 63.4M | 64.0M | 120.3M |
| Earnings per share, basic | 0.27 | 0.13 | 0.10 | 0.06 | 0.16 | 0.16 | 0.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 624.0M | 462.2M | 377.4M | 358.0M | 373.7M | 430.1M | 334.3M |
| Short-term investments | 340.0M | 500.0M | 580.1M | 542.0M | 601.0M | 65.0M | |
| Receivables | 106.1M | 99.3M | 96.8M | 96.9M | 76.4M | 61.6M | 33.1M |
| Inventory | 40.9M | 33.4M | 28.2M | 25.3M | 24.9M | 24.5M | 13.1M |
| Current assets | 1.21B | 1.19B | 1.18B | 1.15B | 1.19B | 1.15B | 487.4M |
| Goodwill | 119.4M | 58.7M | 58.5M | 65.6M | 79.3M | 81.9M | |
| Total assets | 1.95B | 1.76B | 1.73B | 1.67B | 1.71B | 1.69B | 635.4M |
| Accounts payable | 42.5M | 18.0M | 11.3M | 18.6M | 53.6M | 10.8M | 11.1M |
| Current liabilities | 256.2M | 188.7M | 86.0M | 73.8M | 127.1M | 222.4M | 73.0M |
| Long-term debt | 138.5M | 93.5M | 193.7M | 197.5M | 194.1M | 101.1M | |
| Total liabilities | 447.3M | 334.0M | 346.6M | 341.7M | 397.9M | 407.3M | 123.6M |
| Shareholders' equity | 1.50B | 1.39B | 1.36B | 1.30B | 1.32B | 1.28B | 511.8M |
| Shares outstanding | 400.7M | 400.7M | 400.7M | 400.7M | 400.7M | 400.7M | 360.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 216.3M | 128.0M | 125.2M | 52.7M | 43.5M | 1.59M | 168.3M |
| Capital spending | -160.5M | -71.7M | -53.7M | -87.3M | -139.9M | -82.7M | -61.3M |
| Free cash flow | 55.8M | 56.3M | 71.5M | -34.6M | -96.4M | -81.1M | 106.9M |
| Dividends paid | -34.0M | -31.3M | -11.0M | -27.6M | -23.6M | -50.3M | |
| Change in cash | 159.8M | 88.0M | 16.2M | 10.9M | -83.1M | 94.3M | 129.5M |
Filings
All 58 filings
Cap table
Built by 6ix from Hitgen Inc. Class A’s releases
- Common shares
- 401,172,710
- Fully diluted
- 401,172,710
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 401,172,710 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 401,172,710 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dengfeng Dou | Vice President · Since at least Nov 6, 2026 |
| Guansai Liu | Senior Vice President · Since at least Nov 6, 2026 |
| Hongge Liu | Chief Financial Officer · Since at least Nov 6, 2026 |
| Jin Li | Chairman&CEO · Since at least Apr 29, 2026 |
| JJ Chen | Vice President · Since at least Nov 6, 2026 |
| Shimiao Yu | Vice President · Since at least Nov 6, 2026 |
| Shiwei Geng | Board Secretary · Since at least Nov 6, 2026 |
| Suibo Li | Director · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Hitgen Inc.